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In addition, Abs to the T-cell molecule CTLA-4, which is also thought to suppress T-cell responses on interaction with CD80 or CD86 on antigen-presenting cells, are given to treat melanoma as well as prostate and lung cancers. 5, 7 Molecules that participate in the negative regulation of the antitumor response of immune cells are thus promising targets for cancer therapy, with drugs that target such molecules being known as immune checkpoint inhibitors. 8 We and others have recently shown that blocking Abs to SIRPα, which is highly expressed in macrophages and DCs, also has the potential to function as immune checkpoint inhibitors-that target innate immunity, in particular-for cancer treatment.
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2 | SIGNAL REGULATORY PROTEIN α AND
ITS BIOLOGICAL FUNCTIONS
Signal regulatory protein α (also known as SHPS-1, p84, BIT, or CD172a) is a transmembrane protein that was originally identified as a highly expressed glycoprotein in the brain and a binding partner or putative substrate for 2 cytoplasmic-type protein tyrosine phosphatases, SH2 domain-containing phosphatase 1 (Shp1, also known as PTPN6) and Shp2 (PTPN11). [12] [13] [14] [15] Indeed, SIRPα contains 3 Ig-like domains in its extracellular region and 4 tyrosine residues that are putative phosphorylation sites in its cytoplasmic region (Figure 1A) . 16, 17 The extracellular region of SIRPα interacts with its ligand, CD47, which was originally identified in association with α v β 3 integrin and is also a member of the Ig superfamily of proteins, with an Ig-Vlike extracellular domain, 5 putative membrane-spanning segments, and a short cytoplasmic tail ( Figure 1A ). 18 In their phosphorylated state, the tyrosine phosphorylation sites (in particular, the 2 COOHterminal sites) in the cytoplasmic region of SIRPα bind to the SH2 domains of Shp1 and Shp2 and thereby activate these phosphatases ( Figure 1A ). Tyrosine phosphorylation of the cytoplasmic region of SIRPα is triggered by various growth factors and cytokines as well as by integrin-mediated cell adhesion to extracellular matrix proteins. 14, 19 Ligation of SIRPα by CD47 also promotes tyrosine phosphorylation of its cytoplasmic region. 20, 21 SIRPα thus functions as a docking protein for the recruitment and activation of Shp1 and Shp2 at the cell membrane in response to extracellular stimuli, 16 27 Moreover, SIRPα mutant mice, as well as CD47-deficient mice,
were resistant to the development of autoimmune animal models, such as experimental autoimmune encephalomyelitis, 28, 29 suggesting that the interaction of SIRPα with CD47 is involved in the development of autoimmune diseases. SIRPα and CD47 are also thought to play a role in the regulation of central nervous system functions. Both SIRPα mutant mice and CD47-deficient mice, indeed, showed prolonged immobility Although the N-terminal IgV-like domain of human SIRPα, which is responsible for the interaction with CD47, is known to be highly polymorphic, 31 any relationship between such polymorphisms of SIRPα and the incidence of diseases has not been reported so far.
| BINDING OF CD4 7 TO SIRPα

PREVENTS PHAGOCYTOSIS IN MACR OPHAGES
Oldenborg and colleagues 20, 32 first showed that the rate of clearance of transfused CD47-deficient RBCs from the bloodstream of WT mice was markedly increased compared with that of transfused WT cells. 20, 32 In addition, the phagocytosis of CD47-deficient RBCs by isolated splenic macrophages from WT mice in vitro was greatly enhanced compared with that of WT RBCs. 20 We also subsequently 
| Targeting of CD47
CD47 was shown to be identical to the tumor antigen OV-3, which interacts with integrins and is markedly upregulated in ovarian carcinoma cells. 42 Expression of CD47 was also found to be increased in Moreover, an engineered recombinant SIRPα protein, which has a higher affinity for CD47 than does the WT protein and prevents endogenous CD47-SIRPα interaction, was found to significantly enhance the efficacy of therapeutic Abs such as rituximab, trastuzumab, and alemtuzumab (an Ab to CD52) in mouse xenograft models of human cancer. 50 In addition to its effect on ADCP of tumor cells by macrophages, CD47 blockade promotes the activation of tumor-specific cytotoxic T cells by DCs or macrophages. 40, 44, [51] [52] [53] Treatment of tumor-bearing mice with blocking Abs to CD47 thus promoted the recognition of tumor-derived DNA through the stimulator of interferon genes (STING) pathway. 52 Such recognition increased type I interferon production by DCs and enhanced the cross-priming of tumor-specific cytotoxic T cells. 53 Tumor-infiltrating macrophages were also found to participate in the cross-priming of tumor-specific cytotoxic T cells. 51 Blockade of CD47-SIRPα interaction is thus thought to promote the phagocytosis of tumor cells by macrophages and DCs, which, in turn, activate tumor-specific cytotoxic T cells at the site of tumor rejection.
In contrast, given that CD47 is expressed on most cell types, off-target effects of CD47 blockade on normal cells-in particular, erythrocytes -is a potential concern with regard to treatment with drugs that target CD47. Indeed, treatment with Abs to CD47 induced in a dosedependent way the development of transient anemia associated with reticulocytosis in cynomolgus monkeys. 
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Of interest, treatment with blocking Abs to SIRPα did not induce obvious adverse effects including anemia in mice. 11 Treatment of mice with Abs to SIRPα also did not cause any obvious neurotoxicity regardless of the high expression of SIRPα in the neuron. 11 Such Abs might thus be worth pursuing for cancer therapy, especially for the treatment of melanoma and renal cell carcinoma.
| Therapeutic drugs targeting CD47 or SIRPα
Several biological agents, including Abs and recombinant proteins, that are able to bind to human CD47 specifically and block the human CD47-SIRPα interaction have been developed for cancer treatment (Table 1 ). Hu5F9-G4 was the first drug to be developed as a humanized mAb to human CD47. 47 This agent enhances the (Table 1) .
| COMBINATION OF BLOCKING Abs TO CD4 7 OR TO SIRPα WITH IMMUN E CHE CKPOINT INHIBITORS
Treatment with immune checkpoint inhibitors that target PD-1, PD-L1, or CTLA-4 provides substantial clinical benefit in patients with a wide range of malignancies including metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer. [5] [6] [7] However, many Combi, combination therapy; CRC, colorectal carcinoma; ID, clinicaltrials.gov identifier; MDS, myelodysplastic syndrome; MM, multiple myeloma; Mono, monotherapy; NHL, non-Hodgkin lymphoma; PD-1, programmed cell death-1; PD-L1, programmed cell death-ligand 1; PEG-IFN-α2a, pegylated interferon-α2a; SIRPα, signal regulatory protein α; T-Vec, talimogene laherparepvec. 
